- €14.09bn
- €14.09bn
- €1.89bn
Brief: Orion To Continue To Explore Outsourcing In Kuopio
Bayer says 2024 sales of prostate cancer drug above $1 bln
Top of the Street: Orion, Nibe, Hiscox
Jefferies downgrades Orion on Nubeqa 'over-reliance'
Europe Research Roundup: Allianz SE, Halma, ITM Power Plc
Brief: Orion Investigates Possible Outsourcing Of Pharmaceutical Production In Kuopio
Orion drops to bottom of STOXX on worse-than expected Q4 EBIT, outlook
Brief: Orion Proposes Dividend Of EUR 1.62 Per Share For 2023
Brief: Orion Q4 Operating Profit EUR 92.9 Million Vs. Estimate EUR 73 Million
Earnings Poll: Orion Oyj fourth quarter results due on February 13
Brief: Orion, Newel Health Enter Into Licensing Agreement
Brief: Orion Appoints René Lindell As CFO
Brief: Orion Appoints René Lindell Appointed As CFO
Brief: Veli-Matti Mattila Proposed As Orion Chairman
Brief: Orion Portfolio Transfer Expected To Have EUR 31 Mln Positive Impact 2023 Results
Brief: Orion And Glykos Announce Research Collaboration
Brief: Orion, MSD Initiate Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
Brief: Navamedic Says Co And Orion Corporation Sign Non-Binding Term Sheet For Flexilev In Europe
Brief: Orion Animal Health Gets FDA Approval For Bonqat®